Sonoma Biotherapeutics
South San Francisco
About Sonoma Biotherapeutics
Sonoma Biotherapeutics develops engineered regulatory T-cell (Treg) therapies aimed at treating autoimmune and inflammatory diseases by restoring immune system balance. The company employs proprietary cell-therapy platform technologies to engineer and deliver targeted Treg approaches designed for durable, disease-modifying treatment. Its services include preclinical development, clinical evaluation of Treg-based therapies, and collaboration frameworks for advancing new modalities in immune-mediated conditions. Sonoma Biotherapeutics engages with partners and stakeholders across research, manufacturing, and clinical operations to bring engineered cell therapies from concept toward clinical proof of concept.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $365.3M
- Last round: Grant (Nov 2025)
- Website: sonomabio.com
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sonoma-biotherapeutics-117940 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.